Ann: Prestigious Research Journal Publish HER-Vaxx Phase 1B Data, page-17

Nice summary of what we already know from the 1b.
" In contrast to patients in C1 and C2, all patients in C3 mounted substantial HER2-specific Ab levels. Additionally, cellular vaccine responses such as Th1-biased cytokine ratios and reduced Treg numbers were generated. Progression free survival was prolonged in C3, correlating with the vaccine-specific humoral and cellular responses."

PROLONGED.... it works

And its SAFE

Only a few weeks more to wait until we see the PFS data from the phase 2,

I wouldnt be surprised to see it look something like this:
Chemo only patients PFS 5 months.
Chemo plus Her-Vaxx PFS 9 months . With a saftey /side effects profile the big selling mAbs could never envisage.

Pharma partnership deal becomes a foregone conclusion.
The dollar value gets interesting.

Imagine HerVaxx becoming declared the new Standard of Care. Why wouldn't it ???

wake up call....our Mc has yet got a long way to run if this is the case!!!